Financial Performance - The company's operating revenue for Q1 2023 was ¥252,624,843.19, a decrease of 10.55% compared to ¥282,409,086.05 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥19,937,378.89, down 48.11% from ¥38,424,186.65 in the previous year[4] - Basic and diluted earnings per share decreased by 57.14% to ¥0.03 from ¥0.07 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥252,624,843.19, a decrease of 10.55% compared to ¥282,409,086.05 in the same period last year[33] - Net profit for Q1 2023 was ¥22,746,832.35, a decline of 43.1% from ¥39,987,940.47 in Q1 2022[34] - The company reported a total comprehensive income of CNY 13.31 million for Q1 2023, down from CNY 37.56 million in Q1 2022, representing a decrease of approximately 64.5%[35] Cash Flow and Investments - The net cash flow from operating activities was -¥552,283.38, a significant decline of 101.28% compared to ¥43,163,856.04 in Q1 2022[5] - Investment activities resulted in a net cash outflow of -¥90,049,150.51, a 262.24% increase in outflow compared to -¥24,858,973.21 in Q1 2022[15] - The company's cash and cash equivalents at the end of Q1 2023 were ¥542,250,586.83, down from ¥551,740,866.95 at the beginning of the year[28] - Cash inflow from financing activities was CNY 266.89 million in Q1 2023, slightly up from CNY 264.91 million in Q1 2022, indicating a marginal increase of about 0.7%[38] - The company incurred a total cash outflow from investing activities of approximately CNY 91.69 million in Q1 2023, compared to CNY 26.45 million in Q1 2022, reflecting an increase of about 246.5%[37] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥4,539,980,705.12, reflecting a 1.90% increase from ¥4,455,360,858.16 at the end of the previous year[5] - Total liabilities increased to ¥1,408,722,691.31 from ¥1,342,112,749.33, marking a rise of 4.3%[30] - Accounts receivable decreased to ¥236,155,952.46 from ¥337,100,542.93, indicating a reduction of approximately 30%[28] - Inventory increased to ¥1,103,569,076.12, up from ¥925,365,285.72, reflecting a growth of 19.3%[29] - The total equity attributable to shareholders of the parent company was ¥3,079,952,329.49, up from ¥3,064,759,634.69, reflecting a growth of 0.5%[31] Operational Highlights - The company reported a significant increase in construction in progress, rising 1155.16% to ¥25,644,380.82 due to ongoing projects[10] - The company experienced a 300.40% increase in contract liabilities, reaching ¥8,898,539.92, attributed to an increase in advance payments received[10] - The company reported a significant increase in R&D expenses, which rose to ¥11,642,233.61 from ¥9,354,723.77, an increase of 24.4%[34] - The company is advancing the construction of its stevia extraction factory and natural health product research institute, expected to commence production by the end of 2023[21] - The company is focusing on enhancing its competitive advantage through innovation in process research and development, technology transformation, and supply chain diversification[21] Shareholder Information - The top shareholder, Qin Benjun, holds 36.57% of the shares, amounting to 271,389,592 shares, with 129,200,000 shares pledged[18] - The company has raised a total of RMB 967.99 million through a private placement of 165,470,085 shares, with a net amount of RMB 961.11 million after expenses[25] Market and Product Insights - The company reported a significant impact on profits due to stable or slightly declining product prices amid high raw material costs for stevia and monk fruit[20] - The company is committed to maintaining a strong growth trajectory in the natural health products sector, driven by increasing consumer demand for natural and healthy products[21] - The company has completed 64.59% of the contract performance with Firmenich, totaling USD 22.28 million out of a contract amount of USD 34.5 million[23] - The company has a remaining procurement target amount of USD 12.22 million for 2023 under the contract with Firmenich, with a completion confidence for the remaining transaction volume[24]

答:目前高纯 CBD 及相关产品的价格约为 200-300 美元/公斤左右， 整体的供需关系还是呈现供大于求的状态，但我们预计随着市场需求的 增长和行业库存的消耗，将逐步转换为供小于求的状态。谢谢。 4.公司目前是如何处理附属产品 THC 的？未来 THC 是否能带来营收 增长。 答:您好，公司工业大麻提取过程中随之产生的副产品 THC 严格按照 当地最新法律法规进行相应处置，现阶段在政策未放开的情况下（包括 运输、销售等多方面）将选择储存的方式，未来销售将视法规政策而定。 谢谢。 5.国内代糖发展的怎么样？未来趋势怎么样？ 证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2023-006 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及 人员姓名 | 通过"价值在线"平台参与公司 年度网上业绩说明会的投资者 2022 | | 时间 | 年 月 日 2023 4 13 | | ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2023－019 桂林莱茵生物科技股份有限公司 4、出席人员：董事长兼总经理秦本军先生，副总经理兼董事会秘书罗华阳 先生，财务总监郑辉女士，独立董事连漪先生，保荐代表人韦东先生（如遇特殊 情况，参会人员可能进行调整）。 二、征集问题事项 为充分尊重投资者、提升公司与投资者之间的交流效率及针对性，现就公司 2022 年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。投资者可于 2023 年 04 月 12 日前进行会前提问，公司将通过本次业绩说明 会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）2022 年年度报告已 于 2023 年 3 月 29 日披露，为使广大投资者进一步了解公司 2022 年度经营情况， 公司定于 2023 年 4 月 13 日（星期四）在价值在线（www.ir-online.cn）召开 2 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,400,737,343.44, representing a 32.99% increase compared to ¥1,053,235,426.39 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥178,745,385.35, a 50.92% increase from ¥118,438,152.08 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥149,067,554.85, up 74.66% from ¥85,345,120.37 in 2021[20]. - The company's total assets at the end of 2022 were ¥4,455,360,858.16, a 36.71% increase from ¥3,259,000,827.99 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥3,064,751,877.97, reflecting a 64.01% increase from ¥1,868,651,254.39 at the end of 2021[20]. - The basic earnings per share for 2022 was ¥0.29, an increase of 38.10% compared to ¥0.21 in 2021[20]. - The weighted average return on equity for 2022 was 7.76%, up from 6.48% in 2021[20]. - The company achieved a total revenue of 1.4 billion yuan in 2022, with the natural sweetener business contributing 889 million yuan, becoming the main driver of revenue growth[48]. - In 2022, the company achieved total revenue of CNY 1,400.74 million, a year-on-year increase of 32.99%, and a net profit attributable to shareholders of CNY 178.75 million, up 50.92% from 2021, marking historical highs for both revenue and profit[62]. Cash Flow and Investments - The cash flow from operating activities for 2022 was negative at -¥258,422,111.78, a decline of 1,084.84% compared to ¥26,240,101.96 in 2021[20]. - The net cash flow from operating activities turned negative at -¥258,422,111.78, a significant decline from the previous year's positive cash flow[88]. - Investment cash flow net decreased by 189.77%, mainly due to an increase in investment of CNY 183 million from participating in the equity offering of Guilin Bank[89]. - Financing cash flow net increased by 15,337.09%, primarily due to net proceeds of CNY 961 million from a private placement[89]. - The company raised a total of RMB 967,999,997.25 through a non-public offering of 165,470,085 shares at a price of RMB 5.85 per share[104]. - The company temporarily supplemented working capital with RMB 498,500,000 from the raised funds, and RMB 400,000,000 was used for cash management[104]. Market and Industry Insights - The global plant extract market size in 2022 was approximately $34.4 billion, with a significant portion of the demand coming from the food and beverage sector, which accounts for nearly 50% of the market[31]. - The global plant extract market is expected to reach a market size of $59.4 billion by 2025, driven by increasing consumer demand for natural and healthy products[32]. - The company is the first listed entity in the domestic plant extract industry, recognized as a national-level specialized and innovative small giant enterprise, and a national-level green factory[38]. - The company ranks among the top three global suppliers of natural sweeteners, with a strong production and sales capability in stevia and monk fruit extracts[44]. - The natural sweetener market is expanding rapidly, with steviol glycosides expected to exceed $1.6 billion by 2028, driven by consumer demand for natural and sugar-free options[120]. Research and Development - The company has obtained 119 invention patents by the end of the reporting period, reflecting its strong focus on research and development[47]. - The company has established a research and development team led by returnee PhDs and set up a Plant Science Innovation Center to enhance its technological capabilities[152]. - The company is actively developing new products and technologies, including the microbial synthesis technology for natural sweeteners, to enhance its product value[52]. - The company is focusing on upgrading existing products through new technologies and equipment, aiming to accelerate the development and commercialization of synthetic biology technologies[152]. Corporate Governance - The company emphasizes risk-oriented principles in its internal control system to effectively mitigate operational risks[192]. - The company has established a complete governance structure with a board of directors, supervisory board, and various committees, ensuring independent decision-making and oversight[161]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal requirements[160]. - The company has revised and improved 20 governance documents to enhance its internal control and governance structure[159]. Social Responsibility - The company provided a subsidy of 600 RMB per mu for the cultivation of monk fruit, covering 4,680 mu and benefiting 1,468 local farmers, with a total subsidy amount exceeding 2.7 million RMB[199]. - The company actively participated in social responsibility initiatives, including support for rural left-behind women in Guilin, providing care and living supplies[200].

证券代码：002166 证券简称：莱茵生物 编号：2017-001 桂林莱茵生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 五矿证券有限公司 信用市场部 黄剑芳 | | 人员姓名 时间 | 2017 年 5 月 17 | 日 15：00 | | 地点 | 公司总部五楼会议室 | | | | | | | 上市公司接待人 员姓名 | | 副总经理兼董事会秘书罗华阳、董事会办公室专员韦萍 | | 投资者关系活动 | | 一、公司主营产品和核心竞争力是什么？公司成立至今 | | 主要内容介绍 | 主要经 ...